Podcast with Eduardo Bravo – TiGenix – and Samantha Parker – Lysogene – on Adoption of New technologies

12 May 2016

Facing the current challenges of coming to market with new ATMPs in Europe, particularly from the standpoint of the barriers to Adoption; this podcast aims to explore in depth several of the topics around funding and commercialising ATMP technologies in Europe.

Europe is producing excellent ATMP technologies, but there are many barriers to reaching patients and surviving in the market and the EU is starting to bleed promising technology companies to the United States, what does Europe need to do to fix this problem?


1) What are some EU ATMP technologies that are showing promise, or have been commercialised?

2) Give an overview of the current EU funding situation moving from Phase II to Phase III; “the valley of death”

3) How is the situation around reimbursement in Europe developing? What are the core problems? Does the hospital exemption help or hurt?

4)What are some tangible actions that should be taken to arrest the “brain drain” of promissing SMEs working in Europe?

Check out the podcast here.

2017-08-31T12:20:45+00:00May 12, 2016|